151 related articles for article (PubMed ID: 7530585)
1. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
Cheeseman SH; Havlir D; McLaughlin MM; Greenough TC; Sullivan JL; Hall D; Hattox SE; Spector SA; Stein DS; Myers M
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):141-51. PubMed ID: 7530585
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine triple combo results released.
Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362346
[TBL] [Abstract][Full Text] [Related]
4. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.
Saag MS; Emini EA; Laskin OL; Douglas J; Lapidus WI; Schleif WA; Whitley RJ; Hildebrand C; Byrnes VW; Kappes JC
N Engl J Med; 1993 Oct; 329(15):1065-72. PubMed ID: 7690462
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
6. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
[TBL] [Abstract][Full Text] [Related]
7. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
de Jong MD; Loewenthal M; Boucher CA; van der Ende I; Hall D; Schipper P; Imrie A; Weigel HM; Kauffmann RH; Koster R
J Infect Dis; 1994 Jun; 169(6):1346-50. PubMed ID: 8195615
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
[TBL] [Abstract][Full Text] [Related]
11. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
12. New combo trial/same old style.
Gilden D
GMHC Treat Issues; 1995 Apr; 9(4):9. PubMed ID: 11362369
[TBL] [Abstract][Full Text] [Related]
13. Nevirapine surprise.
Smart T
GMHC Treat Issues; 1996; 10(6/7):25. PubMed ID: 11363640
[TBL] [Abstract][Full Text] [Related]
14. AZT plus 3TC produces best results to date.
Grodeck B
Posit Aware; 1995; ():6. PubMed ID: 11362209
[TBL] [Abstract][Full Text] [Related]
15. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
[TBL] [Abstract][Full Text] [Related]
16. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
Thistle P; Spitzer RF; Glazier RH; Pilon R; Arbess G; Simor A; Boyle E; Chitsike I; Chipato T; Gottesman M; Silverman M
Clin Infect Dis; 2007 Jan; 44(1):111-9. PubMed ID: 17143826
[TBL] [Abstract][Full Text] [Related]
18. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
Carr A; Vella S; de Jong MD; Sorice F; Imrie A; Boucher CA; Cooper DA
AIDS; 1996 Jun; 10(6):635-41. PubMed ID: 8780818
[TBL] [Abstract][Full Text] [Related]
20. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
Richman DD; Havlir D; Corbeil J; Looney D; Ignacio C; Spector SA; Sullivan J; Cheeseman S; Barringer K; Pauletti D
J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
